Home › Funds › Fidelity › Fidelity Disruptive Medicine ETF
Fund family: Fidelity · Filed by FIDELITY COVINGTON TRUST (CIK 945908) · SEC series S000079688
Ticker: FMED (C000240928)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 521 with, 4 against, 0 abstentions (not counted as with management); 3 items carried no recommendation. Shareholder proposals: 0 FOR, 4 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Fidelity’s manager page (1,165,189 ballot items across 406 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Fidelity | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 93.3% | 492 | 94.1% | 974,562 |
| Backed environmental and social shareholder proposals at US companies | n/a | 1 | 6.8% | 11,096 |
Each ballot item this fund voted is set against the votes of the other Fidelity funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Fidelity funds on 3 items (0.6% of the 496 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Fidelity funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Stoke Therapeutics, Inc. | 2026-06-03 | Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Julie Anne Smith | Withhold | FOR — 14 of 27 Fidelity funds | Against | Passed (calculated), 86.9% support |
| Sartorius Stedim Biotech SA | 2026-03-24 | Approve Compensation Report of Corporate Officers | For | AGAINST — 7 of 13 Fidelity funds | For | — |
| Sartorius Stedim Biotech SA | 2026-03-24 | Approve Remuneration Policy of CEO | For | AGAINST — 7 of 13 Fidelity funds | For | — |
Download all 3 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 81.1% of this fund’s 525 such votes could be given a sector; the other 99 (18.9%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 375 | 4 | 1.1% |
| Industrials | 32 | 0 | 0.0% |
| Technology | 19 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 314 | 0 |
| Audit-related | 69 | 0 |
| Say-on-Pay | 59 | 0 |
| Corporate Governance | 33 | 3 |
| Compensation | 32 | 0 |
| Capital Structure | 23 | 0 |
| Extraordinary Transactions | 2 | 0 |
| Shareholder Rights and Defenses | 2 | 0 |
| Other Social Issues | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Moderna, Inc. | May 6, 2026 | $6M | 5 | 0 |
| argenx SE | May 6, 2026 | $3M | 12 | 0 |
| argenx SE | November 18, 2025 | $3M | 1 | 0 |
| Danaher Corporation | May 5, 2026 | $3M | 14 | 0 |
| 10x Genomics, Inc. | June 4, 2026 | $2M | 5 | 0 |
| LifeStance Health Group, Inc. | June 2, 2026 | $2M | 4 | 0 |
| Veeva Systems Inc. | June 17, 2026 | $2M | 10 | 0 |
| Edwards Lifesciences Corporation | May 7, 2026 | $2M | 12 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| April 30, 2026 | Boston Scientific Corporation | Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting." Shareholder proposal | Against | For |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
535 ballot items at 67 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Fidelity Disruptive Medicine ETF (FMED) voted at 67 shareholder meetings of 66 companies, on 535 ballot items in all. Where management made a recommendation, the fund followed it on 99.2% of the items and voted against it 4 times. Its most frequent area of disagreement was corporate governance (3 of its votes against management). It voted on 4 shareholder proposals. It voted FOR the board's own proposals less often than Fidelity's funds as a whole (93.3% against 94.1%). It voted differently from most Fidelity funds on 3 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Fidelity’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.